% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • rakanobo rakanobo Dec 23, 2013 9:25 AM Flag

    Is it Smart to Take Some Profits Now?

    Here in the last few weeks I've been seeing a lot of "should I cash out of GALE to invest elsewhere, with more upside" posts. While it is always a good idea to limit risk and diversify your portfolio, there really isn't a better combination of strong data, cheap stock, and high sales potential in the market.

    Strong Data - NeuVax decreased recurrence in almost 80% of patients in the arm of its Phase 2 study that is being tested in Phase 3. It's important to remember that this is the group of patients being tested, those who responded so well to NeuVax.

    Cheap Stock/ High Sales -- GALE has a $400m market cap and could earn $4-$5 billion globally with NeuVax. ARIA's drug now has peak sales of about $300 million following its new label warnings and its decreased chance of label expansion. Other biotechs usually trade with market caps that exceed their peak sales potential, but not GALE, meaning it could be a $4-$5 billion company by the time Ph 3 data is announced in 3 years. That's more upside than anywhere else in the market.

    The bottom line is that there really isn't a better upside scenario in biotechnology, especially one with such a low risk. I remember last year when many thought that GALE was a sell at $1.80, and my feeling is that by next year, we'll be saying the same about $4.

    I believe that GALE is the next PCYC.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.45-0.02(-4.26%)Jul 22 4:00 PMEDT